NCT07459543 2026-03-09
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
Phase 4 Not yet recruiting
Clinical Trials
4 trialsNCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT07092410 2025-07-29
SuRage-EB
SRH Wald-Klinikum Gera GmbH
Phase 4 Not yet recruiting
NCT06785974 2025-01-22
SPIRAL
Erasmus Medical Center
Phase 4 Not yet recruiting